/
Nephrology
Dialysis Patients
13
Pipeline Programs↗
11
Active Trials↗
17
Companies Involved↗
Dialysis Patients is an emerging landscape with 13 programs across 17 companies. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical8
Nandrolone Decanoate
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Furosemid Hydrochlorothiazide
Capital Medical University
Nasal Swabs
Centre Hospitalier Universitaire de Saint Etienne
Lipitor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Colecalciferol
University of Turku
Phase 1
No programs
Phase 32
Approved
No programs
Analysis
Trial Status
147
clinical trials
Completed97 · 66%
Unknown status22 · 15%
Terminated12 · 8%
Recruiting6 · 4%
Withdrawn4 · 3%
Not yet recruiting3 · 2%
Other3 · 2%
Clinical Trials
Trial Activity
147 trials
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Recruiting·—·Phase 2·NCT06929169·80 enrolled
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Active, not recruiting·—·Phase 3·NCT06759077·126 enrolled
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Not yet recruiting·—·Phase 4·NCT07417215·60 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)